Display options
Cite
Müller MJ. Clinical Practice Associated with a Switch from and to Ziprasidone during Routine Inpatient Treatment of Patients with Schizophrenia. Schizophr Res Treatment. 2011;2011:317368doi: 10.1155/2011/317368.
Müller, M. J. (2011). Clinical Practice Associated with a Switch from and to Ziprasidone during Routine Inpatient Treatment of Patients with Schizophrenia. Schizophrenia research and treatment, 2011317368. https://doi.org/10.1155/2011/317368
Müller, Matthias J. "Clinical Practice Associated with a Switch from and to Ziprasidone during Routine Inpatient Treatment of Patients with Schizophrenia." Schizophrenia research and treatment vol. 2011 (2011): 317368. doi: https://doi.org/10.1155/2011/317368
Müller MJ. Clinical Practice Associated with a Switch from and to Ziprasidone during Routine Inpatient Treatment of Patients with Schizophrenia. Schizophr Res Treatment. 2011;2011:317368. doi: 10.1155/2011/317368. Epub 2011 Oct 27. PMID: 22937263; PMCID: PMC3420656.
Copy Download .nbib Format: NLM
Share it on

Schizophr Res Treatment. 2011;2011:317368. doi: 10.1155/2011/317368. Epub 2011 Oct 27.

Clinical Practice Associated with a Switch from and to Ziprasidone during Routine Inpatient Treatment of Patients with Schizophrenia.

Schizophrenia research and treatment

Matthias J Müller

Affiliations

  1. Clinic for Psychiatry and Psychotherapy Giessen and Marburg, Vitos Clinical Centre Giessen-Marburg, Academic Teaching Hospital, University of Giessen, Licher Strasse 106, 35392 Giessen, Germany.

PMID: 22937263 PMCID: PMC3420656 DOI: 10.1155/2011/317368

Abstract

Ziprasidone (ZIP) shows a low propensity for metabolic side effects but can prolong QTc time. It is unclear how these features translate into clinical reality. Charts of inpatients with schizophrenia and switched from (ZIP - , n = 27) or to ZIP (ZIP + , n = 24) were reviewed. Clinical data including documented switch reasons were anonymously analyzed. Comorbidity, body mass index (BMI) at admission, illness severity, side effects, illness duration, and length of stay were comparable in both groups. About 2/3 of ZIP+ were women (1/3 of ZIP - , P = 0.035); ZIP+ patients were younger (P = 0.017), had higher BMI values (P = 0.042), and received higher chlorpromazine equivalents before switch (P = 0.004) whereas ZIP doses were comparable (136 versus 141 mg/d). More patients in ZIP- versus ZIP+ were switched because of previous weight gain (P = 0.006) and depression (P = 0.085) whereas single reasons for ZIP- versus ZIP+ were mainly persisting positive symptoms (P = 0.089) and patients' choice (P = 0.10). The results of the naturalistic study corroborate controlled trials.

References

  1. Clin Neuropharmacol. 2010 May;33(3):121-5 - PubMed
  2. Int Clin Psychopharmacol. 2009 Sep;24(5):229-38 - PubMed
  3. Expert Opin Pharmacother. 2010 Sep;11(13):2199-220 - PubMed
  4. J Clin Psychopharmacol. 2009 Feb;29(1):26-32 - PubMed
  5. Schizophr Res. 2007 Aug;94(1-3):99-106 - PubMed
  6. Cochrane Database Syst Rev. 2009 Oct 07;(4):CD006627 - PubMed
  7. Psychopharmacology (Berl). 1996 Mar;124(1-2):57-73 - PubMed
  8. Eur Neuropsychopharmacol. 2010 May;20(5):310-6 - PubMed
  9. Int Rev Psychiatry. 2010;22(2):138-47 - PubMed
  10. J Clin Psychiatry. 2003 Jun;64(6):663-7 - PubMed
  11. BMC Psychiatry. 2010 Sep 28;10:75 - PubMed
  12. Schizophr Res. 2010 Nov;123(2-3):225-33 - PubMed
  13. Curr Drug Saf. 2010 Jan;5(1):97-104 - PubMed
  14. J Pharmacol Exp Ther. 1995 Oct;275(1):101-13 - PubMed
  15. Eur Psychiatry. 2007 Apr;22(3):195-202 - PubMed
  16. Prog Neuropsychopharmacol Biol Psychiatry. 2010 Aug 16;34(6):997-1000 - PubMed
  17. J Clin Psychiatry. 2007;68 Suppl 7:1-48 - PubMed
  18. Eur Arch Psychiatry Clin Neurosci. 2005 Jun;255(3):190-201 - PubMed
  19. J Psychiatr Pract. 2010 Mar;16(2):103-14 - PubMed
  20. Mol Psychiatry. 2009 Apr;14(4):429-47 - PubMed
  21. Cochrane Database Syst Rev. 2010 Dec 08;(12):CD006629 - PubMed
  22. Biol Psychiatry. 2010 Feb 1;67(3):255-62 - PubMed
  23. CNS Spectr. 2008 Oct;13(10):898-905 - PubMed
  24. Schizophr Res. 2009 May;110(1-3):103-10 - PubMed
  25. Psychopharmacol Bull. 2007;40(3):58-68 - PubMed
  26. J Clin Psychopharmacol. 2010 Aug;30(4):425-30 - PubMed
  27. J Psychiatr Pract. 2002 Mar;8(2):81-97 - PubMed
  28. J Eval Clin Pract. 2010 Aug;16(4):744-55 - PubMed
  29. CNS Drugs. 2009 Aug;23(8):649-59 - PubMed
  30. J Clin Psychopharmacol. 2010 Apr;30(2):176-80 - PubMed

Publication Types